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Abstract
Background: Origanum vulgare Linn has traditionally been used in the treatment of urolithiasis. Therefore, we
investigated the crude extract of Origanum vulgare for possible antiurolithic effect, to rationalize its medicinal use.
Methods: The crude aqueous-methanolic extract of Origanum vulgare (Ov.Cr) was studied using the in vitro and in
vivo methods. In the in vitro experiments, supersaturated solution of calcium and oxalate, kidney epithelial cell lines
(MDCK) and urinary bladder of rabbits were used, whereas, in the in vivo studies, rat model of urolithiasis was used
for the study of preventive and curative effect.
Results: In the in vitro experiments, Ov.Cr exhibited a concentration-dependent (0.25-4 mg/ml) inhibitory effect on
the slope of nucleation and aggregation and also decreased the number of calcium oxalate monohydrate crystals
(COM) produced in calcium oxalate metastable solutions. It also showed concentration-dependent antioxidant
effect against DPPH free radical and lipid peroxidation induced in rat kidney tissue homogenate. Ov.Cr reduced the
cell toxicity using MTT assay and LDH release in renal epithelial cells (MDCK) exposed to oxalate (0.5 mM) and
COM (66 μg/cm
2) crystals. Ov.Cr relaxed high K
+ (80 mM) induced contraction in rabbit urinary bladder strips, and
shifted the calcium concentration-response curves (CRCs) towards right with suppression of the maximum
response similar to that of verapamil, a standard calcium channel blocker. In male Wistar rats receiving lithogenic
treatment comprising of 0.75% ethylene glycol in drinking water given for 3 weeks along with ammonium chloride
(NH4Cl) for the first 5 days, Ov.Cr treatment (10-30 mg/kg) prevented as well as reversed toxic changes including
loss of body weight, polyurea, crystalluria, oxaluria, raised serum urea and creatinine levels and crystal deposition in
kidneys compared to their respective controls.
Conclusion: These data indicating the antiurolithic activity in Ov.Cr, possibly mediated through inhibition of CaOx
crystallization, antioxidant, renal epithelial cell protective and antispasmodic activities, rationalizes its medicinal use
in urolithiasis.
Background
Urolithiasis, the formation of urinary stones, is one of the
oldest known diseases. Archaeological findings give pro-
found evidence that humans have suffered from kidney
and bladder stones for centuries, even examinations of
Egyptian mummies have revealed kidney and bladder
stones [1].
It is the third most common problem of the urinary
tract with an estimated lifetime risk of 2-5% in Asia,
8-15% in Europe and America and around 20% in the
Middle East. It is associated with high rate of recurrence,
which is around 10-23% per year, 50% in 5-10 years and
75% in 20 years. Once afflicted, the subsequent relapse
rate is increased and the recurrence interval is shortened
[2-5]. Moreover, its annual incidences are increasing and
also the age of onset is decreasing, perhaps due to change
in life styles, diet and climate [6].
Improvement in therapy of kidney stones with modern
techniques like extracorporeal shock wave lithotripsy
(ESWL), ureteroscopy (URS), and percutaneous nephro-
lithotomy (PNL), has revolutionized the urological practice
but the recurrence in kidney stone is not altered. ESWL is
less effective in calcium oxalate monohydrate (COM) and
cystine stones than calcium oxalate dihydrate (COD) and
uric acid stones [7]. In addition to the high cast and the
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ple side effects, which include renal damage, ESWL
induced hypertension, renal impairment, sever haematuria,
steinstrasse (multiple small stone blocking ureter),
pancreatitis, infection and persistent residual fragments as
potential nidus for new stone formation. While these com-
plications can lead to large perfusion of the collecting sys-
tem, extravasations of irrigating fluid, urosepsis, ureteral
injury and delayed bleeding may also occur [8,9]. Pharma-
cological agents include a limited choice like citrate and
thiazide diuretics, which have limited efficacy in addition
to their less tolerability [10,11]. On the other hand, there
is growing interest of public in herbal medicine, particu-
larly in the treatment of urolithiasis partly because of lim-
ited choice in the pharmacotherapy. Moreover, herbal
remedies are known to contain multiple constituents,
acting through multiple pathways needed in urolithiasis,
for example, antispasmodic, diuretic, pain relieving
[12,13]. In this study, we evaluated Origanum vulgare L
for its antiurolithic activity, in an attempt to rationalize its
folkloric use in urolithiasis and to see if it exhibits calcium
oxalate crystallization inhibitory, antioxidant, renal cell
protective, antispasmodic and diuretic activities, which are
likely to contribute in its antiurolithic effect. Origanum
vulgare Linn (family, Lamiaceae) is distributed throughout
Asia, Europe and North America [14] and is commonly
known as Wild Marjoram and Winter Sweet and locally
in Pakistan as Mirzanjosh, Sathra [15,16]. It is widely used
in the traditional medicine as lithotriptic, diuretic and
antispasmodic along with other medicinal uses, such as
stimulant, expectorant, antibacterial, anticancer, anti-
inflammatory, antioxidant and laxative [15-17].
Methods
Chemicals and reagents
All chemical used were of analytical grade. List and
sources of chemical used in the study are provided in the
additional file 1.
Animals
Experiments were performed in compliance with the rul-
ings of the Institute of Laboratory Animal Resources,
Commission on Life Sciences, National Research Council
[18] and approved by the Ethical Committee for Research
on Animals (ECRA) of the Aga Khan University, Karachi,
Pakistan.
Wistar rats (180-220 g) of either sex used for this study
were sourced locally and housed at the animal house of
the Aga Khan University, kept in plastic cages (47 × 34 ×
18 cm3) with saw dust (renewed after every 48 hrs), under
a controlled temperature of 23-25°C and 12 hrs light-dark
cycle. Animals had access to food and water ad-libitum
throughout the study. However, food was withdrawn
24 hrs before and during 6 hrs of diuretic study, and while
collecting 24 hrs urine samples.
Plant material and extraction
The plant of Origanum vulgare was collected from the
Northern Areas of Pakistan, identified by taxonomist Prof.
Jhandar shah, Vice chancellor Shaheed Benazir Bhutto
University, Khyber Pakhtunkhwa, Pakistan and voucher
specimen (OV-PL-02-08-72) was submitted to the herbar-
ium of the Department of Biological and Biomedical
Sciences, the Aga Khan University, Karachi. The aerial
part of the plant material was cleaned of adulterants and
kept soaked for three days in the aqueous-methanol
(30:70) with occasional shaking, at room temperature. The
filtration was carried out using a muslin cloth and then
through Whatman qualitative grade 1 filter paper. This
procedure was repeated twice and then all the filtrates
obtained were combined and concentrated on a rotary
evaporator (RE-111, Buchi, Flawil, Switzerland) accompa-
nied with B-700 recirculation chiller and a water bath
model 461 at 40°C to a thick pasty mass called as crude
extract (Ov.Cr), yielding approximately 12% [19,20].
Preliminary phytochemical analysis
The crude extract of Origanum vulgare, was screen for the
presence of different phytochemical groups such as alka-
loids, saponins, coumarins, sterols, terpenes, tannins and
flavonoids by using methods followed previous studies
[21,22].
In vitro experiments
In vitro crystallization studies
Kinetic study The effect of the test material on kinetics
of calcium oxalate (CaOx) crystallization was determined
by the time course measurement of turbidity changes
due to the crystal nucleation and aggregation after mix-
ing metastable solutions of calcium (Ca
++) and oxalate
(Ox). Stock solutions of CaCl2 (8.5 mM) and Na2C2O4
(1.5 mM), containing 200 mM NaCl and 10 mM sodium
acetate were adjusted to pH 5.7 [23]. An aggregometer
(Chrono-Log Corporation, USA) devised for platelet
aggregation studies based on the measurement of optical
density at 620 nm was used to investigate the event of
CaOx crystallization [24]. The slopes of nucleation (SN)
and aggregation phases (SA) were calculated using linear
regression analysis. Using the slopes, the percentage inhi-
bition was calculated as [(1-Sm/Sc) × 100], where Sm is
slope in the presence of modifier; K.Cit or Ov.Cr, and Sc
is slope of the control experiment.
Incubation study To determine the effect of incubation
on CaOx crystal formation, stock solutions of CaCl2 and
Na2C2O4 similar to those in the kinetic study were used.
CaCl2 solutions, containing different concentrations of the
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flat-bottomed tubes in a 24 well plate (Iwaki Microplate
with lid, Scitech Div., Asahi Techno Glass, Japan). To each
of these tubes sodium oxalate (Na2C2O4) solution (0.5 ml)
was added [25]. The plates were then incubated in a shak-
ing water bath at the 90 oscillations/min at a temperature
of 37°C for 45 minutes. Abundance and the morphology
of the crystals in each tube were then observed under
inverted microscope (Nikon Corporation, Tokyo, Japan).
Determination of antioxidant activity
Antioxidant potential of the test materials was estimated
in vitro by free radical scavenging and lipid peroxidation
inhibitory activities.
Free radical scavenging activity
For free radical scavenging activity, a 0.1 mM solution of
2,2-Diphenyl-1-picrylhydrazyl (DPPH) radical in metha-
nol was prepared and 1 ml of this solution was added to
3 ml of the test material at different concentrations pre-
pared in methanol [26]. Solutions were incubated for
30 min at room temperature and then absorbance was
measured at 517 nm. Decreasing of the DPPH solution
absorbance indicates an increase of the DPPH radical-
scavenging activity.
Lipid peroxidation inhibitory activity
To assess lipid peroxidation inhibitory activity, the kid-
neys isolated from Wistar rat were homogenized with
electric homogenizer (Zero-Max
®), in ice cold PBS
(50 mmol/l, pH 7.4) as described earlier [27].
Cell lines (MDCK) Experiment
MDCK cells were maintained as sub-confluent mono-
layers at 37°C in 5% CO2. The culture were grown in
75 cm
2 Falcon tissue culture flasks in a 1:1 DMEM
nutrient mixture and F-12 medium (DMEM/F-12) con-
taining 10% FBS, 2% streptomycin/penicillin, pH 7.4.
The medium was changed every 3 to 4 days.
XTT assay for cell viability
Media was aliquoted to designated wells, containing con-
fluent MDCK cells, of a 96 well plate. The XTT Cell Via-
bility Assay Kit was used to determine the cell viability.
Cells were incubated with and without (Control) plant
extracts for 24 hrs. Then 50 μL of the working activation
solution, prepared by mixing of one bottle of XTT solu-
tion and one of the activation reagent PMS supplied with
kit, was added to all the samples and control, and incu-
bated for 2-4 hrs. Optical density absorbency was read at
450-490 nm on a Bio-Rad 3550 microplate reader (Bio-
Rad, Hercules, CA).
Lactate Dehydrogenase (LDH) Release
Media was aliquated to designated wells of a 96 well
plate. The CytoTox 96 Non-Radioactive Cytotoxicity
assay kit was used to determine LDH percent release.
S u b s t r a t e( s u p p l i e dw i t hk i t )w a sa d d e dt oa l ls a m p l e s ,
positive control (MDCK cells lysed with lysis solution-
supplied with kit), and blanks (acclimazation media). The
plate was incubated at room temperature for 30 minutes
in the dark. Stop solution (supplied with kit) was added
to all samples, positive control, and blanks. Optical den-
sity absorbency was read at 490 nm on a Bio-Rad 3550
microplate reader (Bio-Rad, Hercules, CA).
Antispasmodic activity
Antispasmodic activity of the plant extract was evaluated
against carbachol (CCh) and high K
+ (80 mM)-induced
contractions in strips of rabbit urinary bladder [28]. The
whole urinary bladder of rabbit was dissected out, and
divided into 3-4 vertical strips. Each preparation was
mounted in a 10-20 ml tissue bath containing Kreb’s-
Henseleit solution, maintained at 37°C and continuously
aerated with carbogen. A tension of 1 g was applied to
each tissue throughout the experiment. Isometric
responses were recorded on a Grass Model Polygraph
and/or Power lab 4/24 data acquisition system attached
to computer running Chart 5.3 software (AD Instru-
ments, Sydney, Australia). The tissues were allowed to
equilibrate for a period of about 1 hr before the addition
of any drug, during which the tissue was washed with
fresh bathing fluid at an interval of every 15-20 minutes.
Following the equilibrium, preparations were stabi-
lized, by repeatedly treating with 1 μMC C h ,u n t i lc o n -
stant responses were recorded. Then the spasmolytic
activity of the plant extract was determined by adding
the plant extracts on CCh or high K
+-induced sustained
contraction in rabbit bladder, in a cumulative fashion to
obtain concentration-dependent inhibitory response
[29]. IC50 values (concentration causing 50% inhibition)
were calculated from these curves and calculated as a
measure of spasmolytic potency of the relaxant drugs.
Calcium channel blocking activity
The concentration-response curves (CRCs) of Ca
++ were
constructed in the absence and presence of increasing
concentrations of test drug to confirm the Ca
++ antagonist
action of the test substance. The tissue was allowed to sta-
bilize in normal Kreb’s-Henseleit solution, which was then
replaced with Ca
++-free Kreb’s-Henseleit solution contain-
ing EGTA (0.1 mM) for 30 min in order to remove Ca
++
from the tissues. This solution was further replaced with K
+-rich and Ca
++-free Kreb’s-Henseleit solution. Following
an incubation period of 30 min, CRCs of Ca
++ were con-
structed in the absence and the presence of different con-
centrations of the test materials [30]. Isometric responses
were recorded on a Grass Model 7 Polygraph and/or
Power lab 4/24 data acquisition system attached to com-
puter running Chart 5.3 software (AD Instruments,
Sydney, Australia).
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Determination of diuretic activity
The diuretic activity of the test material was studied on
Wistar rats of either sex (180-220 g) as described pre-
viously [31]. Animals were divided with matched body
weight and sex into groups of 6 animals each. Normal and
positive control groups were given by gavages saline
(20 ml/kg) and standard diuretic drug: hydrochlorothia-
zide (HCT), 10 mg/kg of body weight, respectively. The
rest of the groups were given different doses of the test
material dissolved in saline. Subsequently, the animals
were placed individually in metabolic and diuretic cages.
The urine was collected in graduated cylinders for 6 hrs at
2 hrs intervals. Total urine excreted out was collected and
the volume was determined.
Study on animal model of urolithiasis
Antiurolithic activity of the test material was determined
using animal model of CaOx urolithiasis [32,33]. Male
Wistar rats (weighing 180-220 g) were divided with
matched body weights into groups of 6-8 animals each,
which were then randomly selected to receive various
treatments for preventive and curative study.
Preventive study model To study the preventive effect of
the test material, rats serving as normal control, received
intra-peritoneal (i.p.) injections of normal saline (2.5 ml/
kg), once in 24 hrs. Whereas, untreated group received i.p.
injection of normal saline (2.5 ml/kg) along with renal
CaOx crystal deposits inducing (lithogenic) treatment for
21 days. The renal CaOx deposits induction was achieved
by giving water containing 0.75% (w/v) ethylene glycol
(EG) and 1% (w/v) ammonium chloride (AC) for 5 days,
following this the water supply was switched to 0.75% EG
alone [32,33]. Treated groups received i.p. injection of the
extract dissolved in saline once in 24 hrs and simulta-
neously received crystal deposits inducing treatment simi-
lar to the untreated group. Based on the medicinal use
and literature available on Origanum vulgare, where doses
of 20-60 mg/kg have been used in rats [34,35], we used
log doses 10 and 30 mg/kg for its diuretic and antiurolithic
effect, optimized in our pilot study. Animal weight and
activity were regularly monitored to assess their overall
health and those looking lethargic or who have lost exces-
sive weight were excluded from the study. Water intake
was determined and 24 hrs urine samples were collected
immediately before the onset and at the end of total 21
days of treatment, for which animals were housed indivi-
dually in metabolic and diuretic cages. The 3 hrs morning
urine for crystalluria study was also collected before col-
lecting 24-hrs urine at the end of 21 days of treatments.
The number of the crystals/mm
3 was counted under light
microscope using haemocytometer.
Curative study model In the study for the curative
effect, CaOx deposits were induced in the kidneys of
rats in both untreated and treated groups with EG
(0.75%) and AC (1%) treatment for 21 days, following
the plan as given with the study on the preventive effect.
Thereafter, lithogenic treatment was withdrawn and
treatment with vehicle and the test material was respec-
tively started to the untreated and the treated groups for
another period of 14 days [33]. Normal control, received
no treatment for the first 21 days study period, but
received i.p. injections of normal saline (2.5 ml/kg), dur-
ing the next 14 days. Animal weights and their activity
were regularly monitored, whereas, 24 hrs urine samples
were collected immediately before and after the crystals
deposits induction (lithogenic) treatment and at the end
of total treatment period (35 days). 3-hrs urine sample
was collected after both 21 and 35 days.
Following volume and pH determination, 24 hrs urine
samples were stored at -20°C until analyzed. Blood was
collected through cardiac puncture from animals under
ether anaesthesia for serum separation in order to assess
serum creatinine and blood urea nitrogen (BUN). Animals
were sacrificed and the kidneys were fixed in 10% neutral
buffered formalin, processed, embedded in paraffin wax,
sectioned at 5 μm and stained with Haematoxylin and
Eosin (H & E) and by Pizzolato’s method, for calcium
oxalate crystals [36], for microscopic examination.
Calcium oxalate crystal deposition in kidney
Crystal distribution within the kidneys was determined
by using the semiquantitaive scoring by the methods
used by Vanachayangkul et al., [37]. Briefly the crystal
deposits in stained sections with visible in a field of 10×
magnification were counted and severity grades were
assigned as 0 = < 1 crystals, 1 = ≤ 10, 2 = ≤ 30, 3 = ≤ 50,
4=≤ 75 and 5 = > 75 crystals. Most of the crystals were
located in the outer modularly and cortical region of the
kidney.
Biochemical analysis of urine and serum
Urine samples for Ox, Ca
++ and Mg
++ ,c i t r a t e ,a n du r i c
acid (UA) and serum samples for creatinine and BUN
contents were determined by using commercially avail-
able kits (Company names for kits are given in the addi-
tional file), while urinary inorganic phosphate and
protein were determined by using the molybdenum blue
reaction [38] and Lowry’s [39] method respectively.
Data Analysis
The data expressed are mean ± standard error of mean
(SEM) and the median effective concentration (EC50
value) with 95% confidence intervals (CI). All statistical
comparisons between the groups are made by means of
t- test (comparison between two groups) or One Way
Analysis of Variance (ANOVA) with post hoc Dunnett’s
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CRCs were analyzed by non-linear regression using
GraphPad Prism (GraphPad Software, San Diego, CA,
USA).
Results
Phytochemical Screenings
The phytochemical test showed the presence of sapo-
nins, alkaloids, coumarins, sterol, terpenes, flavonoids
and tannins in Ov.Cr.
In vitro Experiment
Effect on in vitro crystallization
Kinetic study Effect of Ov.Cr on various phases of CaOx
crystallization as determined by time course measurement
of turbidity under standard conditions (4.25 mM Ca
++ and
0.75 mM Ox) is given in Figure 1, which shows typical tra-
cing (Figure 1A and 1B) of the experiment in the presence
of Ov.Cr and potassium citrate. In the control curve, the
initial rise in turbidity; the nucleation phase, on attaining
its maximum after about 150 ± 15 sec, followed by a slow
Figure 1 Calcium Oxalate crystallization study. Effect of Origanum vulgare (Ov.Cr) and Potassium Citrate (k-Cit) on calcium oxalate
crystallization. (A) and (B) are the typical tracing of the control and in the presence of Ov.Cr and potassium citrate. Panel (C) is concentration-
response curves of Ov.Cr and potassium citrate on SA of the turbidity curves, while (D) shows the % inhibition on the SN. Symbols shown are
mean ± S.E.M. (n = 3). SN and SA represent slope of nucleation and slop of aggregation respectively.
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with a median inhibitory concentration of 0.47 mg/ml
(0.31 to 0.69; 95% CI), similar to potassium citrate which
causes inhibition with IC50 value of 0.42 mM (0.31 to 0.58;
9 5 %C I )a ss h o w ni nF i g u r e1 C .O v . C rc a u s e d1 0±1 . 7 3 ,
16 ± 2.3, 20 ± 1.7 and 35 ± 2.8% inhibition of SN at the
concentration of 0.5, 1, 2 and 4 mg/ml, while the citrate
caused 20 ± 1.7, 31 ± 2.31, 42 ± 4.0 and 65 ± 4.2% inhibi-
tion at a concentration of 0.5, 1, 2 and 4 mM, respectively
(Figure 1D).
Incubation study In the incubation study, mixing the
metastable solutions of Ca
++ and Ox resulted in the for-
mation of CaOx crystals, predominately of the dumbbell
shaped calcium oxalate monohydrate (COM). Ov.Cr
caused a concentration-dependent (1-4 mg/ml) decrease
in the CaOx crystal formation (Figure 2A &2B) and also
decreased the number and size of COM crystals; similarly
citrate also decreased the number and size of crystals
formed (Figure 2C &2D).
Antioxidant activity
Free radical scavenging activity Ov.Cr caused inhibi-
tion of DPPH free radical with IC50 value of 6.28 μg/ml
(5.41 - 7.27; 95% CI), while the control drug butylated
hydroxytoluene (BHT) inhibited DPPH with IC50 value
of 3.41 μg/ml (3.16 - 3.68; 95% CI) as shown in the
Figure 3A.
Lipid peroxidation inhibitory activity Ov.Cr inhibited
the in vitro lipid peroxidation induced in rat kidney
Figure 2 Calcium Oxalate incubation study. Representative photographs, under inverted microscope (200x), of CaOx crystals developed in the
metastable solutions in the absence (A and C) and in the presence of crude extract of Origanum vulgare (Ov.Cr) 2 mg/ml (B) and 2 mM K-Citrate
(D).
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while BHT caused 30.8 ± 2.6 and 71.6 ± 3.8% inhibition
of lipid peroxidation at 50 and 150 μg/ml, respectively
(Figure 3B).
Effect on Kidney Epithelial Cell Lines (MDCK)
Effect on cell viability Ov.Cr had no toxic effect on
MDCK cells up to 0.1 mg/ml. However, it significantly
(p < 0.01) reduced the cell viability at higher concentra-
tions (Figure 4A).
Effect Ov.Cr on MDCK cells after exposure to Oxalate
and COM crystals The cell viability was decreased (p <
0.001) after exposure to 0.5 mM Ox or 66 μg/cm
2 of
COM. However, after the co-exposure of Ov.Cr, the cell
viability was mildly increased at 0.03 mg/ml while signif-
icantly (p < 0.01) increased as compared to Ox or COM
at a concentration of 0.1 mg/ml (Figure 4B and 4C).
Effect of Ov.Cr on cell membrane damage LDH release
was significantly increased (p < 0.001) after exposure to
0.5 mM Ox or 66 μg/cm
2 COM vs. untreated control.
However, co-exposure of Ov.Cr (0.1 and 0.3 mg/ml) sig-
nificantly decrease the LDH release (Figure 4D and 4E).
Effect on Urinary bladder
Ov.Cr caused concentration-dependent inhibition of
both CCh (1 μM) and high K
+ (80 mM)-induced con-
tractions in rabbit urinary bladder preparations (Figure
5A) with an EC50 values of 0.061 (0.04-0.08) and 0.068
mg/ml (0.05-0.08) respectively. Similarly, verapamil was
f o u n dt ob em o r ep o t e n ta g a i n s tt h eK
+ than the CCh-
induced contraction. It relaxed both CCh and K
+-induced contractions (Figure 5C) with IC50 values of
0.08 μM (0.07-0.10) and 0.04 μM (0.03-0.5) respectively.
Ov.Cr (0.03-0.1 mg/m1) caused rightward shift of the
Ca
++ CRCs accompanied by suppression of the
maximum contractile effect, similar to that caused by
verapamil (0.01-0.03 μM), as shown in Figure 5B and
5D.
In vivo experiments
Diuretic effect
Ov.Cr increased significantly (p < 0.05) the urine output
in Wistar rats at the dose of 10 mg/kg, while there was
no affect seen at lower (3 mg/kg) or higher dose
(30 mg/kg). HCT (10 mg/kg) was used as reference
drug, which significantly (p < 0.01) increased the urine
output (Figure 6).
Effect on animal model of Urolithiasis
Preventive effect In preventive study, all the parameters,
like body weights, 24 hrs water intake, urine volume,
urinary pH and composition, recorded before the treat-
ment were not significantly different among the groups.
The parameters recorded at day 0 and at the end of 3
weeks of treatment period are listed in the additional
file 2.
In the 3-hrs morning urine sample of rats, significantly
more and bigger CaOx crystals mostly of COD were
observed in lithogenic group as compared to the saline
group. Whereas, Ov.Cr significantly reduced urinary crys-
tal count as well as decreased crystal size (Figure 7). At the
end of the treatment a significant (p <0 . 0 1v s .N o r m a l )
loss in body weights was caused by the EG and AC con-
sumption in the lithogenic group as compared to the nor-
mal saline group. The co-administration of Ov.Cr (10-30
mg/ml) prevented the loss in body weights of rats (p <
0.01 vs. lithogenic group). 24 hrs urine volume and water
intake were higher (p < 0.01) in the lithogenic group com-
pared to that of normal saline animals. Urine pH was also
Figure 3 Antioxidant activity. Concentration-response curves of the free radical scavenging activity of the butylated hydroxytoluene (BHT) and
Ov.Cr, while bar-chart (B) representing lipid peroxidation inhibitory activity of two different concentrations of Ov.Cr and BHT. Inhibition is
measure as % of the respective control experiments. The values shown are mean ± SEM (n = 3).
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protective effect of Ov.Cr after exposure to 0.5 mM oxalate or 66 mg/cm
2 COM respectively. While (D) and (E) shows the percent increase in
LDH release against control by MDCK cells exposed Ox. (0.5 mM) and COM (66 μg/cm
2) for 24 hrs. Data shown are mean ± SEM of two separate
experiments with 3 independent replicates. * p < 0.05, ** p < 0.05 and *** p < 0.001
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ment with Ov.Cr significantly reduced (p < 0.05) polyurea
and water intake compared to lithogenic group. Similarly,
oxalate excretion was significantly increased (p < 0.01) in
lithogenic animals, whereas Ca
++ excretion was decreased
(p < 0.05). Urine contents of citrate, phosphate, UA, Mg
2
+,N a
+ and K
+ did not alter to a significant level. Co-
administration of Ov.Cr (10-30 mg/kg) to lithogenic group
significantly (p < 0.05) decreased oxalate excretion,
whereas urinary excretion of citrate and Ca
2+ was signifi-
cantly increased (p < 0.05). EG treatment caused impair-
ment of renal functions of the untreated rats (lithogenic
group) as evident from total protein loss and raised BUN
and serum creatinine (p < 0.05), which were prevented in
the animals treated with Ov.Cr. (please see additional file
2).
Kidneys excised from lithogenic group were enlarged.
Histological preparations of kidneys of normal saline
Figure 5 Antispasmodic effect. Concentration-response curves of crude extract of Ov.Cr (A) and verapamil (B) on K
+ (80 mM) and CCh (1 μM)-
induced contractions and the concentration-response curves of Ca
++ constructed in the absence and presence of increasing concentrations of
Ov.Cr (C) and verapamil (D) in isolated rabbit urinary bladder. The symbols represent mean ± SEM (n = 4-6).
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high score of crystalline deposits was observed in all
regions of kidneys in the lithogenic group. However, Ov.
Cr treatment significantly lowered the CaOx crystal
deposits (p < 0.5) as compared to untreated (lithop-
genic) group (Figure 8 and 9A).
Curative effect In the curative study, all the parameters
were recorded before start of the treatment (day 0),
after 3 weeks of the crystals deposits induction, and
then two weeks after the withdrawal of the crystals
deposition treatment (0.75% EG + 1% AC in drinking
water). The parameters recorded for the curative study
are given in the Additional file 3.
The groups, which consumed the lithogenic treatment
for the first 21 days, developed the lithogenic parameters
as compared to the normal saline group like in the pre-
ventive study. This was suggested by a net loss in the
body weights, a significant increase in 24 hrs water
intake, urine volume, oxalate, uric acid, total protein,
and decreased urinary pH and Ca
++ contents, impaired
renal function suggested by increased serum creatinine,
BUN and total urinary protein loss (Additional file 3).
Post-induction treatment with Ov.Cr (10 and 30 mg/kg)
reversed the loss in body weights, impaired urinary and
serum functions, crystalluria and deposition of crystals
in the kidney more quickly than the control group
(Additional file 3).
After two weeks of Ov.Cr treatment in the curative
study, renal CaOx crystal deposits were found in 4 out
of 6 rats. However, they were significantly less (p <0 . 5 )
than the untreated group (Figure 9B and Figure 10).
Discussion
In view of the medicinal uses of Origanum vulgare in
urolithiasis, we evaluated its crude extract for the possi-
ble antiurolithic effect along with antioxidant, antispas-
modic and diuretic activities using the in vitro assays
and in vivo rat models.
In this study, the plant extract inhibited the CaOx
crystal nucleation and aggregation in a concentration-
dependent manner, similar to citrate, a well-known inhi-
bitor of CaOx crystallization and clinically used for the
management of urolithiasis [40]. Similarly, in the incu-
bation study, Ov.Cr caused a decrease in crystal count
and transformed COM to COD crystal like that of
citrate and Mg
2+ [41]. COM crystals are considered to
be more harmful than COD because of their tendency
to attach with the membrane to form aggregates [42]
and are more likely to attach with the kidney epithelial
cells than CaOx dehydrate, resulting in the formation of
kidney stones [42,43]. Calcification is a multifactorial
Figure 6 Diuretic effect. Effect of the Ov.Cr and
hydrochlorothiazide (HCT) on urine volume collected in 6 hrs
(values shown are means ± SEM, n = 6-8). * p < 0.05, ** p < 0.01
Figure 7 Images of Crystalluria. Images of calcium oxalate crystals in 3 hrs morning urine collected from Normal control (A), Lithogenic
Control (B) and treated with crude extract of Origanum vulgare(Ov.Cr) (C), under light microscope at 400× magnification.
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Page 10 of 16phenomenon [44], arising as a result of a cascade of
events initiated by supersaturation, including crystal
nucleation, growth, aggregation and retention [45].
Although supersaturation is not the only critical step
involved in the formation of kidney stones as several
studies have identified many inhibitors of calcium oxa-
late and calcium phosphate crystallization including
ionic or macromolecules [46], yet it is the prerequisite
Figure 8 Microscopic images of Kidney sections in preventive study. Representative microscopic images of the H and E stain of the kidney
sections from normal (A), Lithogenic group (B) and Treated (C) with Ov.Cr. A1, B1 and C1 show the polarized images of the sections.
Khan et al. BMC Complementary and Alternative Medicine 2011, 11:96
http://www.biomedcentral.com/1472-6882/11/96
Page 11 of 16for the crystals formation in the urinary tract [47]. Var-
ious crystal inhibitors like potassium-sodium citrate and
magnesium oxide have been shown to decrease the
saturation of CaOx and inhibit crystal nucleation,
growth and aggregation and reduced crystallization in
urine of stone forming patients [48]. Interference with
crystal growth and aggregation therefore seems a possi-
ble therapeutic strategy for the prevention of recurrent
stone disease. Ov.Cr inhibits CaOx crystal nucleation
and aggregation along with decrease in count and mor-
phological change, from COM to COD, in crystals.
These results indicate the presence of CaOx crystal
aggregation inhibitory constituent(s) in the plant.
Animal and cellular studies have revealed that oxalate,
calcium oxalate and hydroxy apatite crystals cause injury
to kidney cells [49,50], caused by the production of
reactive species (ROS) which is considered to be the risk
factor for the crystallization and crystals deposition in
the kidney by promoting crystal nucleation, aggregation,
retention and stone development [49,51]. Antioxidants
such as vitamin E, catechin and selenium have been
shown to protect against oxidative injury by oxalate and
crystal deposition [52,53]. When studied for its antioxi-
dant activity, Ov.Cr caused scavenging of DPPH free
radical and inhibited ferrous-ascorbate-induced lipid
peroxidation of rat kidney homogenate similar to BHT,
a standard antioxidant [54], confirming its antioxidant
activity [35,55,56].
Cytoprotective effect of the plant was confirmed when
pre-treatment of the normal kidney epithelial (MDCK)
cells with Ov.Cr significantly increased the survival rate
and reduced the LDH, a marker of cell membrane
damage [57], release of MDCK cells exposed to Ox and
COM crystals. This protective effect could be the result
of its antioxidant activity.
Antispasmodics are more commonly used in the med-
ical expulsive therapy (MET) for the kidney stones [58].
Administration of alpha-adrenoreceptor antagonists or
Ca
++ channel blockers enhances the expulsion rate of
crystals and reduces colic event [59]. Therefore, we eval-
uated the antispasmodic effect of Ov.Cr, and studied its
relaxant effect against high K
+ (80 mM) and CCh (1
μM) induced contraction, using rabbit urinary bladder
strips. High K
+ (> 30 mM) is known to cause smooth
muscle contraction though opening of voltage depended
L-type calcium channels, thus allowing influx of extra-
cellular Ca
++ resulting in the contraction of the smooth
muscles [20,60] and a substance that relax the high K
+
induced contraction is considered to be CCB [61].
Whereas, CCh is a cholinergic drug, which can induce
contraction in urinary bladder through activation of
muscarinic receptors, predominately M3 subtype [62].
Ov.Cr relaxed the high K
+ and CCh induced contraction
like that of verapamil, a standard CCB [63], indicating
CCB activity, which was confirmed when pre-treatment
of the tissue with the plant material shifted the Ca
++
CRC to the right with suppression of the maximum
response, like that of verapamil.
In the in vivo experiment, Ov.Cr caused significant
increase in urine output at the dose of 10 mg/kg similar
to that caused by HCT, a standard diuretic, while, the
administration of next higher dose (30 mg/kg) did not
caused any significant change in the diuretic effect,
compared to the saline control, which could be due to
the co-existence of anti-diuretic component(s) in Ov.Cr,
as plant extract may exhibit multiple therapeutic activ-
ities probably on account of having a mixture of
Figure 9 Crystals deposits score in Kidney sections of
preventive and curative study. Calcium oxalate crystal deposition
score after treatment with 0.75% EG, 1% NH4Cl (lithogenic group),
Ov.Cr 10 and 30 mg/kg in preventive (A) and curative (B) study
model. Severity grade were assigned as 0 = < 1 crystals, 1 = ≤ 10, 2
= ≤ 30, 3 = ≤ 50, 4 = ≤ 75 and 5 = > 75 crystals; data are
expressed as mean ± SEM. * p < 0.05, ** p < 0.05 and *** p < 0.001
vs. Normal,
# p < 0.05,
## p < 0.01 and
### p < 0.001 vs. Lithogenic
group.
Khan et al. BMC Complementary and Alternative Medicine 2011, 11:96
http://www.biomedcentral.com/1472-6882/11/96
Page 12 of 16phytochemicals. The presence of synergistic and/or side-
effect neutralizing effect in plants is known to exist [12],
which is probably meant by nature not to allow the
pharmacological effect go beyond a certain limit, beyond
which it could have been harmful. Diuretics increase
urine volume, which results in the reduction of supersa-
turation of crystals forming salts and also help in the
expulsion of already formed crystals [64,65].
Figure 10 Microscopic images of Kidney sections in curative study. Representative microscopic images of the H and E of the kidney
sections from normal (A), Lithogenic group (B) and Treated (C) with Ov.Cr. A1, B1 and C1 show the polarized images of the sections.
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Page 13 of 16The antiurolithic effect of Ov.Cr was evaluated on the
most commonly applied EG-induced model for uro-
lithiasis [66-68] and male Wistar rats, which develop
changes in urine electrolytes and CaOx super-saturation
to a greater extent due to their greater sensitivity to EG
toxicity [69], were used.
In this study, hyperoxaluria was induced by adminis-
tration of EG (0.75% in drinking water) for 21 days and
AC (1%) was given only for the first 5 days, as adminis-
tration of AC for more than 5 days led to extreme
weight loss and ultimately death of the rats [37].
In the preventive study, administration of EG and AC
resulted in the increase in crystalluria with larger crys-
tals due to hyperoxaluria, increase in water intake and
urine output, which might be due to the renal impair-
ment [68], as there was significant increase in serum
creatinine, blood urea nitrogen and total protein loss in
lithogenic group as compared to normal, which has
been restored by the Ov.Cr treatment. Consistent with
some previous reports, crystals deposition by hyperoxa-
luria caused an increase in oxalate and decrease in Ca
2+
excretion in the lithogenic group [70,71], which was pre-
vented by Ov.Cr. There was hypertrophy and extensive
calcium oxalate crystal deposition in kidneys of litho-
genic group. The renal tubules were markedly dilated,
which might be due to the obstruction in distal renal
tubular flow by large crystals [68]. Several in vivo and in
vitro studies have demonstrated that hyperoxaluria, a
major risk factor for calcium oxalate nephrolithiasis,
results in production of superoxide and hydroxyl free
radicals causing oxidative stress, cell membrane rupture
and cell death [53,72], and leads to CaOx crystal adher-
ence and retention in renal tubules [53,73]. This can be
speculated that the inhibitory effect of Ov.Cr on calcium
oxalate crystal deposition in renal tubules could have
also been caused by its antioxidant activity.
In curative study, withdrawal of lithogenic treatment
after 21 days evoked a spontaneous recovery of nephro-
lithic animals in the untreated groups. However, Ov.Cr
enhanced the spontaneous recovery in the treated group
than the untreated group, which was clearly shown by
the gain in body weight, significant decrease in urinary
oxalate, renal crystal deposition and improvement in
renal functions compared to the lithogenic group.
Phytochemical screening revealed the presence of
s a p o n i n s ,a l k a l o i d s ,c o u m a r i ns, sterol, terpenes, flavo-
noids and tannins. Different activities observed in the
c r u d ee x t r a c tm i g h tb ed u et ot h ep r e s e n c eo ft h e s e
phytochemicals. For example, flavonoids are known to
possess antispasmodic and Ca
++ channel blocking
[74,75], antioxidant [76] and diuretic [77] activities.
Saponins are known to possess anti-crystallization prop-
erty by disaggregating the suspension of mucoproteins,
promoters of crystallization [9]. However, the
contribution of other phytochemicals accounting for the
reported activities cannot be rule out.
The plant showed antiurolithic activity both in the in
vitro and in vivo models in addition to its antioxidant,
renal epithelial cell protective, antispasmodic and diure-
tic activities reported in this study, all of which could be
beneficial in urolithiasis. The plant is also reported to
possess anti-inflammatory [78] and antimicrobial [79]
activities, which could also be supplementing its benefi-
cial effect, as the infection and inflammation are likely
to be associated with urolithiasis process. Thus, the her-
bal remedies known to contain multiple activities offer
therapeutic potential particularly in the urolithiasis,
where multiple targets are needed. A few studies on the
effectiveness of herbal remedies in urolithiasis exists,
such as Hernaira hirsute, Phylanthus niruri and Hibiscus
sabdariffa, which showed promising results in the man-
agement of urolithiasis [8]. However, most of these stu-
dies were using the in vitro and/or in vivo studies with
limited advancement in the possible mechanisms of
their effectiveness. In this study, we used both the in
vivo and in vitro models along with multiple activities,
as mentioned above, giving comprehensive information
on the pharmacological basis for its effectiveness in uro-
lithiasis. The plant being of edible nature with a long
history of medicinal use is considered to be relatively
safe, however, detailed studies on its safety profile is
needed before recommending for clinical use.
Conclusion
Together these data suggest that the presence of antiur-
olithic effect in Origanum vulgare against renal calcium
oxalate crystal deposits is mediated possibly through a
combination of CaOx crystal inhibitory, diuretic, antiox-
idant, antispasmodic, epithelial cell protective, hypocal-
ciuric and hypercitrauric effects thus acting on multiple
sites. This study rationalizes its medicinal use in the
treatment of urolithiasis.
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